Arovella Therapeutics Ltd has released a press release.
ArTiMist Appeal Lodged With TGA
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- ZolpiMist Clinical Results Published
- European Anagrelide Cancer Patent
- Supplementary Prospectus
- Rights Issue Closes Significantly Oversubscribed
- SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
Later from Arovella Therapeutics
- Manaing Director and CEO Resignation
- Response to ASX Query regarding Accounts
- SUDA Finalises Agreement With Cann Pharmaceutical
- Case For Share Consolidation and Appendix 3A.3
- SUDA Appoints Dr Michael Baker CEO
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics